Gapping up
In reaction to strong earnings/guidance:
- MUX +3.4%
Other news:
- PHAS +28.1% (receives FDA Breakthrough Therapy designation for PB2452 for the reversal of the antiplatelet; provided immediate and sustained reversal of ticagrelor antiplatelet effects in ph I trial)
- CMRX +13.9% (appoints Mike Sherman as CEO and Mike Andriole as Chief Business Officer)
- MTSI +6.7% (still checking; is scheduled to present at Broadcasters conference April 8-11; will showcase its portfolio of cable equalizers, cable drivers, reclockers and crosspoint switches supporting SDI)
- GWPH +3.5% (competitor Zogenix (ZGNX) receives refusal to file letter for its seizure drug)
- AVYA +3.3% (continued strength on LBO speculation)
- BLDP +3.1% (signs supply agreement with Norled for Fuel Cell Modules)
- HA +1.6% (reports total traffic increased 0.2% for March)
Analyst comments:
- GERN +5.4% (upgraded to Buy from Hold at Needham)
- DIS +0.7% (upgraded to Outperform from Market Perform at Cowen)